These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35371270)

  • 21. Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria.
    Sologuren A; Viñas R; Cordón E; Riesgo SE; Del Mar Forés M; Senán MR; Fernández S; Labeaga L; Ruiz-Miján M
    Allergy Asthma Proc; 2018 Jul; 39(4):299-304. PubMed ID: 29559031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria.
    Sadaba B; Azanza JR; Gomez-Guiu A; Rodil R
    Ther Clin Risk Manag; 2013; 9():197-205. PubMed ID: 23667312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial.
    Podder I; Das A; Ghosh S; Biswas D; Sengupta S; Chowdhury SN
    Dermatol Ther; 2020 Nov; 33(6):e13946. PubMed ID: 32618048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation.
    Ochoa D; Román M; Belmonte C; Martín-Vilchez S; Mejía-Abril G; Abad-Santos F; Hernández G; Arranz P; Elgezabal L; Fernández N
    Adv Ther; 2021 Jul; 38(7):4070-4081. PubMed ID: 34125400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria.
    Jáuregui I; García-Lirio E; Soriano AM; Gamboa PM; Antépara I
    Expert Rev Clin Immunol; 2012 Jan; 8(1):33-41. PubMed ID: 22149338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bilastine in Refractory Chronic Spontaneous Urticaria: Disease Control and Cytokine Modulation in an Open-label Prospective Study.
    De A; Singh S; Chakraborty D; Sarda A; Godse K
    Indian J Dermatol; 2024; 69(2):132-136. PubMed ID: 38841225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bilastine: a new H
    Church MK; Labeaga L
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1447-1452. PubMed ID: 28467671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study.
    Zuberbier T; Oanta A; Bogacka E; Medina I; Wesel F; Uhl P; Antépara I; Jáuregui I; Valiente R;
    Allergy; 2010 Apr; 65(4):516-28. PubMed ID: 19860762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety profile of bilastine: 2nd generation H1-antihistamines.
    Scaglione F
    Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1999-2005. PubMed ID: 23242729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria.
    Church MK
    Expert Opin Drug Saf; 2011 Sep; 10(5):779-93. PubMed ID: 21831011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Comparative, Three-Arm, Randomized Clinical Trial to Evaluate the Effectiveness and Tolerability of Bilastine vs Fexofenadine vs Levocetirizine at the Standard Dose and Bilastine vs Fexofenadine at Higher Than the Standard Dose (Up-Dosing) vs Levocetirizine and Hydroxyzine (in Combination) in Patients with Chronic Spontaneous Urticaria.
    Shah B; Dhoot D; Choudhary A; Jangid N; Mistry D; Shah S; Kamat S; Barkate H
    Clin Cosmet Investig Dermatol; 2022; 15():261-270. PubMed ID: 35221703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions.
    Leceta A; García A; Sologuren A; Campo C
    Drugs Context; 2021; 10():. PubMed ID: 34457015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study.
    Serra E; Campo C; Novák Z; Majorek-Olechowska B; Pulka G; García-Bea A; Labeaga L
    J Dermatolog Treat; 2020 May; 31(3):270-278. PubMed ID: 30835579
    [No Abstract]   [Full Text] [Related]  

  • 34. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review.
    Bousquet J; Ansótegui I; Canonica GW; Zuberbier T; Baena-Cagnani CE; Bachert C; Cruz AA; González SN; Kuna P; Morais-Almeida M; Mullol J; Ryan DP; Sánchez-Borges M; Valiente R; Church MK
    Curr Med Res Opin; 2012 Jan; 28(1):131-9. PubMed ID: 22149770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases.
    Novák Z; Yáñez A; Kiss I; Kuna P; Tortajada-Girbés M; Valiente R;
    Pediatr Allergy Immunol; 2016 Aug; 27(5):493-8. PubMed ID: 26918853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Indian Experience of Switchover to Bilastine 40 mg/day in CSU Patient Refractory to Other Antihistamines at Double Dose.
    De A; Shah B; Banodkar PD; Dhoot D; Chitnis K; Barkate H
    Indian J Dermatol; 2023; 68(6):674-677. PubMed ID: 38371575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria.
    Krause K; Spohr A; Zuberbier T; Church MK; Maurer M
    Allergy; 2013 Jul; 68(7):921-8. PubMed ID: 23742030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving.
    Jáuregui I; Ramaekers JG; Yanai K; Farré M; Redondo E; Valiente R; Labeaga L
    Expert Opin Drug Saf; 2016 Jan; 15(1):89-98. PubMed ID: 26571227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selecting optimal second-generation antihistamines for allergic rhinitis and urticaria in Asia.
    Recto MT; Gabriel MT; Kulthanan K; Tantilipikorn P; Aw DC; Lee TH; Chwen CC; Mutusamy S; Hao NT; Quang VT; Canonica GW
    Clin Mol Allergy; 2017; 15():19. PubMed ID: 29118675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought - first results of the multicenter real-life AWARE study.
    Maurer M; Staubach P; Raap U; Richter-Huhn G; Bauer A; Ruëff F; Jakob T; Yazdi AS; Mahler V; Wagner N; Lippert U; Hillen U; Schwinn A; Pawlak M; Behnke N; Chaouche K; Chapman-Rothe N
    Clin Exp Allergy; 2017 May; 47(5):684-692. PubMed ID: 28160338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.